Travere Therapeutics (NASDAQ:TVTX) Price Target Increased to $20.00 by Analysts at HC Wainwright

Travere Therapeutics (NASDAQ:TVTX) had its price target boosted by HC Wainwright from $19.00 to $20.00 in a research report report published on Monday, Benzinga reports. They currently have a buy rating on the stock.

TVTX has been the topic of several other reports. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $15.00 to $18.00 and gave the company a buy rating in a research report on Tuesday, May 7th. Barclays upped their price objective on Travere Therapeutics from $12.00 to $14.00 and gave the company an overweight rating in a research report on Friday. Piper Sandler upped their target price on Travere Therapeutics from $11.00 to $12.00 and gave the company a neutral rating in a research note on Friday. Finally, Wedbush upped their target price on Travere Therapeutics from $13.00 to $16.00 and gave the company an outperform rating in a research note on Friday. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $15.27.

Travere Therapeutics Price Performance

TVTX traded up $0.37 during trading on Monday, reaching $8.90. 1,037,708 shares of the stock were exchanged, compared to its average volume of 1,234,143. The business’s 50 day moving average price is $8.40 and its two-hundred day moving average price is $7.74. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. The company has a market capitalization of $677.56 million, a price-to-earnings ratio of -4.24 and a beta of 0.77. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $15.90.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 207.40%. The company had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $43.46 million. During the same quarter in the prior year, the company earned ($1.27) earnings per share. The firm’s revenue was up 34.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Travere Therapeutics will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Travere Therapeutics by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company’s stock worth $48,310,000 after purchasing an additional 750,686 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after buying an additional 1,995,419 shares during the period. Kynam Capital Management LP raised its holdings in shares of Travere Therapeutics by 105.6% during the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $17,980,000 after buying an additional 1,027,398 shares during the period. Finepoint Capital LP raised its holdings in shares of Travere Therapeutics by 60.2% during the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock valued at $12,904,000 after buying an additional 539,500 shares during the period. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of Travere Therapeutics by 76.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock valued at $9,159,000 after buying an additional 441,318 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.